PharmaFocus Today – Page 79 – media

Another senior executive of Baiyunshan was taken away within half a year

On December 20, Baiyunshan (600332.SH) issued an announcement stating that it had received a written resignation report submitted by Huang Haiwen, the company’s deputy general manager, on the same day. “Due to personal reasons, Huang Haiwen resigned from the position of deputy general manager of the company and all positions in the company’s affiliated enterprises.” Baiyunshan said that after his resignation, Huang Haiwen no longer held all positions in the company and its affiliated enterprises. This is the third senior executive of Baiyunshan to announce his resignation from “all positions” this year, following the resignation of the company’s former chairman Li Chuyuan (later officially announced to be dismissed) in July this year and director Zhang Chunbo in August. Reporters confirmed from multiple independent information sources that Huang Haiwen has been taken away by relevant departments for investigation. It is worth noting that Huang Haiwen, 43 years old, has a resume ...
- Source: drugdu
- 131
- December 28, 2024
FDA approves first “off-the-shelf” mesenchymal cell therapy

The U.S. FDA recently announced that it has approved Ryoncil (remestemcel) developed by Mesoblast for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children aged 2 months and older. The FDA’s press release stated that this is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Ryoncil is a mesenchymal stromal cell produced by allogeneic bone marrow. It regulates T cell-mediated inflammatory responses by inhibiting T cell proliferation and downregulating the production of proinflammatory cytokines and interferons. The safety and efficacy of Ryoncil were verified in a multicenter, single-arm study in which 54 pediatric patients with SR-aGVHD after allo-HSCT participated. Study participants received intravenous infusions of Ryoncil twice a week for a total of four weeks. The main basis for efficacy is the remission rate and duration of remission 28 days after the start of treatment. Results showed that 16 participants (30%) achieved complete remission after 28 days of treatment ...
- Source: drugdu
- 253
- December 28, 2024
Longsha Capsules and Health Ingredients Expand Capsule Production Capacity in China and India

Longsha Capsules and Health Ingredients (CHI) has added new capsule production lines at its factories in Suzhou, China and Ravali, India, demonstrating its long-term strategic commitment to this business segment and the Asia Pacific region. This expansion aims to balance CHI’s global layout, meet regional demand, and promote technological upgrades. Basel, Switzerland, December 19, 2024- Lonza Group, as a manufacturing partner in the global pharmaceutical, biotechnology, and nutritional health markets, announced that its factories in Suzhou, China and Ravali, India will undergo capacity expansion. The expansion project includes the addition of a gelatin hollow capsule (HGC) production line to support the production of high-quality gelatin hard capsules. The types of capsules produced cover both conventional and customized capsules required by the pharmaceutical and nutritional health products industries. This capacity expansion marks another important progress in Longsha CHI’s hollow hard capsule strategy, aimed at enhancing long-term competitiveness and meeting high quality ...
- Source: drugdu
- 128
- December 28, 2024
744 million! Medical equipment dark horse completes Series C financing again

According to the Medicine Intelligence Data Investment Pattern Database, Precision Neuroscience (hereinafter referred to as Precision) recently announced the completion of a new round of $102 million (contract 740 million RMB) Series C financing, bringing its total capital to $155 million. Investors participating in this round of financing include General Equity Holdings, B Capital, Duquesne Family Office of Stanley F. Druckenmiller, and Steadview Capital. This round of financing will be used to expand Precision’s team, advance clinical research work, and refine future versions of its AI driven brain implants. These implants are designed to enable severely paralyzed users to operate digital devices such as computers and smartphones solely through thinking. In addition, according to the Medicine Intelligence Data Investment Pattern Database, Precision also completed a Series C financing on November 6th this year, with a financing scale of 93 million US dollars (contract 679 million RMB). Advanced Brain Computer Interface ...
- Source: drugdu
- 435
- December 28, 2024
Bi Jingquan won the DIA Lifetime Achievement Award, and he opened the chapter of China’s innovative drugs

On December 19, in Washington, the United States, the International Drug Information Association (DIA) awarded Bi Jingquan the DIA Lifetime Achievement Award to thank him for his long-term outstanding leadership and extraordinary courage in promoting drug innovation and international cooperation. The chairman of the China Center for International Economic Exchanges (CCIEE) and former director of the China Food and Drug Administration was once evaluated by the industry as: the best director of the Food and Drug Administration in many years, and is also regarded by many as one of the key figures in promoting the development of China’s innovative drug industry. DIA, which awarded Bi Jingquan this time, is a global, interdisciplinary international academic platform with a high reputation in the field of global pharmaceutical research and development. In 2017, when the Chinese drug regulatory authorities sought to join the International Council for Harmonization of Technical Requirements for Pharmaceuticals for ...
- Source: drugdu
- 236
- December 27, 2024
The first cell impermeable membrane covered stent has been approved by the FDA for market launch

Recently, Merit Medical announced that its non permeable membrane covered stent, Wrapsody, has been approved by the FDA for sale. This is the first product approved by the FDA for the treatment of vascular stenosis or thrombosis in hemodialysis patients. It is reported that Merit Medical will start commercialization in the United States next year.The first heavyweight product has been launched Founded in 1987, Merit Medical is a leading medical device manufacturing enterprise that produces instruments used in cardiac and radiological interventional surgeries. The product line of Merit Medical Company includes interventional filling devices and their accessories, diagnostic and therapeutic catheters and guide wires, disposable pressure monitoring equipment, contrast agent management systems, non vascular stents, thrombolytic catheters, syringes and needles, etc. The company is committed to meeting the needs of global cardiology and radiology experts through product development and high-quality production. Hemodialysis is currently the most widely used blood purification ...
- Source: drugdu
- 138
- December 27, 2024
Jiangsu ProteLight’s antimicrobial peptide product Peceleganan has applied for listing, and CTTQ Pharma has obtained exclusive cooperation rights in China

On December 24, the official website of the Drug Evaluation Center (CDE) of the State Food and Drug Administration announced that the marketing application of Pratt&Lyle’s Class 1 new drug Peceleganan Spray was accepted. In January 2023, CTTQ Pharma signed an exclusive commercial cooperation agreement with Pulei Pharmaceutical regarding the antimicrobial peptide product Peceleganan for the treatment of secondary wound infections in China. Peceleganan (PL-5) spray is a new polypeptide broad-spectrum anti infective drug, which belongs to non antibiotic anti infective drugs and has a unique bactericidal mechanism. According to the pipeline information on the official website of ProteLight Pharma, the fastest indication for the research process of this product is secondary wound infection. Secondary wound infection refers to open wound infection caused by various bacteria, including diabetes foot, bedsore, burn, etc. With the use of antibiotics, the proportion of drug-resistant bacteria is increasing, leading to the serious problem of ...
- Source: drugdu
- 233
- December 27, 2024
In 2023, both revenue and profit will decrease, and Taide Pharmaceutical will once again rush to the Hong Kong stock market for listing

In November, the weight reducing version of semaglutide, also known as “Novo Nordisk”, was officially launched in China. Simeglutide belongs to the GLP-1 (glucagon like peptide-1, a naturally occurring peptide hormone) receptor agonist class of peptide drugs, and Ted Pharmaceutical (Zhejiang) Co., Ltd. (hereinafter referred to as Ted Pharmaceutical) is a company in the related field. After its expiration in May 2024, the company has recently submitted another application to rush for listing on the Hong Kong stock market. According to the prospectus, Ted Pharmaceuticals claims to be the world’s third-largest peptide focused CRDMO (Contract Research, Development, and Production Organization), providing discovery, research, development, and manufacturing services in the pharmaceutical and/or biotechnology industry on a contractual basis. However, the performance of Ted Pharmaceuticals, which is currently in a hot spot, is not satisfactory. In 2023, the company experienced a decline in both revenue and profit. The reporter from the Daily ...
- Source: drugdu
- 136
- December 27, 2024
The original new drug manufacturing base project of Microchip has officially started construction

On the morning of December 24th, the “Pengzhou City Promotion of ‘Establishing a Full Garden’ Action Conference and Pengzhou Microchip Original New Drug Manufacturing Base Project Commencement Ceremony” was successfully held at Tianfu Traditional Chinese Medicine City in Pengzhou Economic Development Zone. It is reported that Shenzhen Weixin Biotechnology Co., Ltd., as the first enterprise to pass the Shanghai Stock Exchange’s Science and Technology Innovation Board and the first original new drug enterprise to list on the board, has been deeply engaged in the research and development of innovative drugs for more than 20 years. It has won the first prize of the National Science and Technology Progress Award and the China Patent Gold Award, ranking 18th on the list of China’s top 100 pharmaceutical innovation enterprises. It is committed to developing original new drugs with great clinical value, achieving multiple breakthroughs in major disease fields, and giving birth to ...
- Source: drugdu
- 279
- December 27, 2024
The first Chinese-led lung cancer targeted drug has been approved by the FDA

Before 2016, if the revenue ratio was used as an identification indicator, all pharmaceutical companies listed on the A-share market were “generic drug” companies. Until the emergence of Beida Pharmaceuticals. Beida Pharmaceuticals was established in 2003 and has long focused on the development of small molecule innovative drugs in the field of lung cancer. Its drug Icotinib is my country’s first small molecule targeted anticancer drug with completely independent intellectual property rights, and it is also the first independent innovative drug with annual sales of more than 1 billion yuan. On November 7, 2016, Beida Pharmaceuticals was successfully listed on the Growth Enterprise Market, becoming the first pharmaceutical company in the A-share market whose main income comes entirely from innovative drugs, and is known as the “first innovative drug stock.” In December 2024, after experiencing the previous layoffs, Beida Pharmaceuticals ushered in another important milestone in its development history. On ...
- Source: drugdu
- 202
- December 27, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.